Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2012-08-30 Declaration of Voting R…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2012
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details a notification pursuant to sections 21 (1), 24 WpHG (German Securities Trading Act) regarding Deutsche Bank AG's subsidiary crossing the 5% threshold of voting rights in STADA Arzneimittel AG. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes and related announcements regarding voting rights thresholds.
2012-08-30 English
Declaration of Voting Results & Voting Rights Announcements 2012
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states 'Voting Rights Announcements' in the header and details a notification pursuant to section 21 (1) WpHG (German Securities Trading Act) regarding a reduction in voting interest by SKAGEN AS, falling below the 3% threshold. This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and contains the announcement itself, not just a notice about an attached report.
2012-08-27 English
STADA signs contract on the sale of two Russian production facilities and thus completes another significant step in the context of 'STADA - build the future'
M&A Activity Classification · 95% confidence The document is explicitly labeled as an 'Ad-hoc' announcement dated August 15, 2012, disseminated according to § 15 WpHG (German Securities Trading Act). Ad-hoc announcements are used to disclose price-sensitive information immediately. The content details a significant corporate transaction: the signing of a contract for the sale of two Russian production facilities, including financial impacts (one-time burden) and restructuring goals ('STADA - build the future'). This type of immediate, material corporate event disclosure does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). Since it is a material, non-standard regulatory disclosure that doesn't fit the specific transaction types (M&A, Capital Change, Dividend), the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers general regulatory announcements.
2012-08-15 English
Declaration of Voting Results & Voting Rights Announcements 2012
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states 'Voting Rights Announcements' in the header and details a notification pursuant to sections 21 (1), 24 WpHG (German Securities Trading Act) regarding the percentage of voting rights held by Deutsche Bank AG's subsidiary falling below a threshold. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements'. The code for this is DVA.
2012-08-15 English
Q2 Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report on the First Six Months of 2012' and contains detailed financial tables (Group sales, EBITDA, EBIT, etc.) and a 'Consolidated Interim MANAGEMENT REPORT' section. It provides a comprehensive analysis of financial performance for a period shorter than a full fiscal year (six months). It is not an announcement of a report, but the report itself, containing substantive financial data and management analysis. H1 2012
2012-08-10 English
STADA records positive business development in the first half of 2012 - outlook remains positive to 2014
Earnings Release Classification · 100% confidence The document explicitly states, "Today, STADA Arzneimittel AG published the financial results for the first half of 2012." It contains detailed financial metrics (sales, EBITDA, net income) broken down by segment (Generics, Branded Products) and geography for the 'first six months of 2012' (1-6/2012). This content structure—a comprehensive financial review for a period shorter than a year—is characteristic of an Interim/Quarterly Report. The code 'IR' (Interim / Quarterly Report) is the most appropriate classification, as opposed to '10-K' (Annual Report) or 'ER' (Earnings Release, which is usually just highlights). H1 2012
2012-08-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.